Document is current
Any future updates will be listed below
-
Authors
Bland, Philip https://orcid.org/0009-0002-1370-0359
Saville, Harry
Wai, Patty T.
Curnow, Lucinda
Muirhead, Gareth
Nieminuszczy, Jadwiga https://orcid.org/0000-0003-4672-9684
Ravindran, Nivedita
John, Marie Beatrix
Hedayat, Somaieh
Barker, Holly E. https://orcid.org/0000-0002-9350-5520
Wright, James
Yu, Lu https://orcid.org/0000-0001-8378-9112
Mavrommati, Ioanna https://orcid.org/0000-0002-5436-2619
Read, Abigail
Peck, Barrie https://orcid.org/0000-0002-6687-8495
Allen, Mark
Gazinska, Patrycja
Pemberton, Helen N.
Gulati, Aditi
Nash, Sarah
Noor, Farzana
Guppy, Naomi
Roxanis, Ioannis
Pratt, Guy
Oldreive, Ceri https://orcid.org/0000-0002-7815-8970
Stankovic, Tatjana https://orcid.org/0000-0002-3780-274X
Barlow, Samantha
Kalirai, Helen
Coupland, Sarah E.
Broderick, Ronan
Alsafadi, Samar https://orcid.org/0000-0002-0060-1346
Houy, Alexandre https://orcid.org/0000-0001-6267-2353
Stern, Marc-Henri https://orcid.org/0000-0002-8100-2272
Pettit, Stephen https://orcid.org/0000-0003-3313-3857
Choudhary, Jyoti S. https://orcid.org/0000-0003-0881-5477
Haider, Syed https://orcid.org/0000-0001-6685-5480
Niedzwiedz, Wojciech https://orcid.org/0000-0002-8518-6304
Lord, Christopher J. https://orcid.org/0000-0002-3226-0515
Natrajan, Rachael https://orcid.org/0000-0002-9987-2946
-
Funding
Funding for this research was provided by:
Breast Cancer Now (programme grant, Programmatic funding)
RCUK | Medical Research Council (MC_PC_16047)
Cancer Research UK (C20807/A28640, C20807/A28640, A24881, Programmatic funding)
Site de Recherche Integree sur le Cancer (SiRIC2) Institute Curie
Wellcome Trust (20839)
- License Information
-
More Information
Article History
Received: 9 March 2023
Accepted: 26 June 2023
First Online: 31 July 2023
Competing interests
: W.N. is a named inventor on a patent describing the use of EXD2 inhibitors and stands to gain from their development as part of the ICR ‘Rewards to Inventors’ scheme, and was a consultant for MNM Bioscience. C.J.L. makes the following disclosures: receives and/or has received research funding from AstraZeneca, Merck KGaA, and Artios; received consultancy from SAB membership or honoraria payments from Syncona, Sun Pharma, Gerson Lehrman Group, Merck KGaA, Vertex, AstraZeneca, Tango, 3rd Rock, Ono Pharma, Artios, Abingworth, Tesselate and Dark Blue Therapeutics; has stock in Tango, Ovibio, Enedra Tx., Hysplex and Tesselate. C.J.L. is also a named inventor on patents describing the use of DNA repair inhibitors and stands to gain from their development and use as part of the ICR ‘Rewards to Inventors’ scheme and also reports benefits from this scheme associated with patents for PARPi paid into CJL’s personal account and research accounts at the Institute of Cancer Research. R.N. receives and/or has received academic research funding from Pfizer in the form of the Breast Cancer Now Catalyst academic grant scheme. AstraZeneca partially supported the PiCCLe clinical trial (supplied by Olaparib; this study is published). The remaining authors declare no conflicts of interest.
